0001104659-26-033592
SEC filingRezolute, Inc. issued a press release announcing outcomes from its March 17, 2026, Type B meeting with the FDA regarding the sunRIZE Phase 3 study of ersodetug for congenital hyperinsulinism, which did not meet its primary endpoint. The FDA encouraged submission of comprehensive data from sunRIZE and the ongoing open-label extension for independent review to inform next steps.